SUO 2017: Retzius-sparing Robotic-assisted Laparoscopic Radical Prostatectomy: A Safe Oncologic Surgical Technique With Superior Continence Outcomes

Washington, DC (UroToday.com) Introduction: Conventional robotic-assisted laparoscopic radical prostatectomy (RALRP) is associated with significant side effects, including urinary incontinence. The authors of this study aimed to compare the peri-operative, oncologic, and functional outcomes of prostate cancer patients undergoing a Retzius-sparing RALRP (RS-RALRP) to those undergoing a conventional RALRP.

Methods: This was a prospective, single-center, consecutive case series of 100 and 100 patients undergoing a RS-RALRP and RALRP, respectively, by a single surgeon between March 2015 and April 2017.

Results: Baseline patient characteristics were similar between the two groups. The Retzius-sparing approach required significantly less console time (120.0 vs. 144.0 mins, p<0.001). There were no differences in intra- or post-operative complication rates, and hospital length of stay was similar in the two groups. Patients in the Retzius-sparing group had significantly superior rates of achieving post-operative urinary continence (log-rank test: p<0.001), with 20% of patients continent within the first month, compared to 8% of patients in the conventional group. Mean number of pads per day needed at three, six, nine, and 12 months post-operatively was also significantly lower in the Retzius-sparing group. Incidence of positive surgical margins was similar among both groups. Similarly, there were no differences in rates of biochemical failure at three and six months post-operatively.

Conclusion: The authors conclude that RS-RALRP requires shorter console time, is oncologically safe, and leads to significantly superior continence outcomes compared to conventional RALRP.

Presented by: Rashid Sayyid, Medical College of Georgia, Augusta University, Augusta, GA, USA

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, @GoldbergHanan, at the 18th Annual Meeting of the Society of Urologic Oncology, November 29-December 1, 2017 – Washington, DC
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe